Bioceltix S.A. (WSE: BCX)

Market Cap	365.40M
Revenue (ttm)	n/a
Net Income (ttm)	-15.72M
Shares Out	4.92M
EPS (ttm)	-3.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	567
Open	74.00
Previous Close	74.00
Day's Range	73.50 - 74.80
52-Week Range	58.90 - 98.00
Beta	1.66
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 25, 2024

About Bioceltix

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 28
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BCX